This finding, if corroborated by future studies, would have some implications for risk stratification, which is central to treatment choices and management strategies in PAH.5 Current metrics such as FC, 6MWD, and BNP enable quick risk stratification in PAH patients in the outpatient clinic setting. The gene discussed is NPPB; the disease is pulmonary arterial hypertension.